No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease (Q91793998)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30789808 AND SRC:MED&resulttype=core&format=json

24 April 2020

title

No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30789808 AND SRC:MED&resulttype=core&format=json

24 April 2020

1 reference

metabolic dysfunction–associated steatotic liver disease

1 reference

L Farzin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30789808 AND SRC:MED&resulttype=core&format=json

24 April 2020

S Asghari

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30789808 AND SRC:MED&resulttype=core&format=json

24 April 2020

M Rafraf

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30789808 AND SRC:MED&resulttype=core&format=json

24 April 2020

M Asghari-Jafarabadi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30789808 AND SRC:MED&resulttype=core&format=json

24 April 2020

M Shirmohammadi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30789808 AND SRC:MED&resulttype=core&format=json

24 April 2020

publication date

21 February 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30789808 AND SRC:MED&resulttype=core&format=json

International Journal for Vitamin and Nutrition Research

24 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30789808 AND SRC:MED&resulttype=core&format=json

24 April 2020

page(s)

1-11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30789808 AND SRC:MED&resulttype=core&format=json

Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease

24 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Prevalence of Nonalcoholic Fatty Liver Disease and its Related Metabolic Risk Factors in Isfahan, Iran

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

NAFLD and liver transplantation: Current burden and expected challenges

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Liver Transplantation for Quality as well as Quantity of Life

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

NAFLD: a multisystem disease.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Non-alcoholic fatty liver disease and risk of cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Current therapies for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol, sirtuins, and the promise of a DR mimetic

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Distinct effects of calorie restriction and resveratrol on diet-induced obesity and Fatty liver formation

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Weight loss in nonalcoholic Fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

A Systematic Review of the Efficacy of Bioactive Compounds in Cardiovascular Disease: Carbohydrates, Active Lipids and Nitrogen Compounds.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol: French paradox revisited

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: A triple-blind, 6-month follow-up, placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Effects of resveratrol and other polyphenols in hepatic steatosis.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol use in metabolic syndrome

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol and pharmacological potentiation in ischemic stroke

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Potential of resveratrol in the treatment of heart failure.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol supplementation: Where are we now and where should we go?

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

The use of guideline images to improve histological estimation of hepatic steatosis

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Nonalcoholic fatty liver disease and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol and cardiovascular health--promising therapeutic or hopeless illusion?

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol suppresses oxidised low-density lipoprotein-induced macrophage apoptosis through inhibition of intracellular reactive oxygen species generation, LOX-1, and the p38 MAPK pathway

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Resveratrol and cardiovascular health

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Appropriate LDL-C-to-HDL-C Ratio Cutoffs for Categorization of Cardiovascular Disease Risk Factors among Uygur Adults in Xinjiang, China

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk: The PREVEND study

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Serum alkaline phosphatase is a predictor of mortality, myocardial infarction, or stent thrombosis after implantation of coronary drug-eluting stent

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Effect of age and gender on the relationship between alcohol consumption and serum GGT: time to recalibrate goals for normal ranges

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

The efficacy of resveratrol in controlling hypertension: study protocol for a randomized, crossover, double-blinded, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Serum concentrations and gene expression of sirtuin 1 in healthy and slightly overweight subjects after caloric restriction or resveratrol supplementation: A randomized trial

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota.

1 reference

https://api.crossref.org/works/10.1024/0300-9831/A000528

7 January 2021

10.1024/0300-9831/A000528

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30789808 AND SRC:MED&resulttype=core&format=json

24 April 2020

1 reference